Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Atugen and Byk Gulden Study T Cells With Antisense

NEW YORK, May 14-The German firm Atugen will collaborate on a three year functional genomics research project with Byk Gulden, the pharmaceutical group of Altana AG.


Atugen will validate genetic targets associated with cancer and immunological disease, and develop "GeneBloc" antisense oligonucleotides against these targets. The two companies will use these probes to jointly conduct functional genomics studies in assays and animal models.


The partnership will especially focus on genetic targets in T cells for treatment of inflammatory disease.


Atugen will get an upfront payment, annual licensing fees, research funding and milestone payments, as well as royalties on any probes developed as therapeutics. The company retains rights to all GeneBloc oligonucleotides, and may further develop any targets not pursued by Byk Gulden.


This collaboration builds upon another established last fall, when the two companies agreed to jointly develop cancer-related gene targets.


Atugen is headquartered in Berlin, with a subsidiary in Boulder, Colo.


Byk Gulden, based in Constance, Germany, specializes in therapeutics for gastrointestinal, respiratory tract, and cardiovascular conditions.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.